Technology Appraisal Virtual Committee Meeting

Committee A

Zoom

## Minutes: Confirmed

## Date and Time: Tuesday 8 September 2020, 09.30am - 4.30pm

### Present:

1. Dr Jane Adam (Chair) Present for all notes
2. Dr Brian Shine (Vice Chair) Present for all notes
3. Dr Peter Baker Present for all notes
4. Mr Richard Ballerand Present for all notes
5. Dr Justin Daniels Present for all notes
6. Dr Steve Edwards Present for notes 9 to 13
7. Dr Rita Faria Present for all notes
8. Dr Khalida Ismail Present for all notes
9. Professor G.J. Melendez-Torres Present for all notes
10. Mrs Becky Pennington Present for all notes
11. Ms Pamela Rees Present for notes 1 to 8
12. Dr Mohit Sharma Present for all notes
13. Mr Stephen Sharp Present for all notes
14. Dr Alice Turner Present for all notes
15. Dr Min Ven Teo Present for all notes
16. Dr Roger Whittaker Present for all notes

### In attendance:

* Janet Robertson, Associate Director, NICE, Present for all notes
* Thomas Feist, Project Manager, NICE, Present for all notes
* Marcia Miller, Administrator, NICE, Present for all notes
* Laura Marsden, Coordinator, NICE, Present for all notes
* Mandy Brereton, Assistant Project Manager, Present for notes 9 to 13
* Juliet Kenny, Technical Analyst, NICE, Present for notes 1 to 8
* Zoe Charles, Technical Adviser, NICE, Present for notes 1 to 8
* Rufaro Kausi, Technical Adviser, NICE, Present for notes 9 to 13
* Richard Mattock, Technical Analyst, YHEC, Present for notes 9 to 13
* Ayeda Nadeem, Technical Analyst, YHEC, Present for notes 9 to 13
* Mariana Bacelar, BMJ-TAG, Evidence Review Group, Present for notes 1 to 4
* Steve Edwards, BMJ-TAG, Evidence Review Group, Present for notes 1 to 4
* Charlotta Karner, BMJ-TAG, Evidence Review Group, Present for notes 1 to 4
* Rob Riemsma, KSR, Evidence Review Group, Present for notes 9 to 10
* Bram Ramaekers, KSR, Evidence Review Group, Present for notes 9 to 10
* Prof Iain McNeish, Clinical Expert, Chair in Oncology, Imperial College London, Present for notes 1 to 4
* Dr Susana Banerjee, Clinical Expert, Consultant Medical Oncologist, Present for notes 1 to 4
* Dr Abd Tahrani, Clinical Expert, Clinical Scientist and Honorary Consultant in Endocrinology, Diabetes and Weight Management, Present for notes 9 to 10
* Prof Carel le Roux, Clinical Expert, Consultant in Metabolic Medicine and Obesity, Present for notes 9 to 10
* Lucy Perrow, Clinical Expert, Clinical Lead Dietician, Present for notes 9 to 10
* Florence Wilks, Patient Expert, Present for notes 1 to 4
* Rachel Downing, Patient Expert, Target Ovarian Cancer, Present for notes 1 to 4
* Sarah Le Brocq, Patient Expert, Director of HOOP UK, Present for notes 9 to 10
* Prof Peter Clark, Cancer drugs Fund Clinical Lead, Present for notes 1 to 8

### Non-public attendees:

* Helen Barnett, Editor, NICE, Present for notes 1 to 8
* Emily Eaton Turner, NICE, Technical Adviser, Present for notes 1 to 8
* Cara Gibbons, NICE, Assistant Technical Analyst, Present for notes 9 to 13
* Claire Hawksworth, NICE, Managed Access, Present for notes 1 to 8
* Sana Khan, NICE, Technical Analyst, Present for notes 1 to 8
* Ria Skelton, Editor, NICE, Present for notes 9 to 13
* Adam Storrow, NICE, Business Analyst, Present for all notes
* Mandy Tonkinson, Public Involvement adviser, NICE, Present for notes 1 to 4

## Notes

### Any other Business

1. None.

### Minutes from the last meeting

1. The committee approved the minutes of the committee meeting held on Tuesday 14 July 2020.

## Appraisal of olaparib in combination with bevacizumab for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy with bevacizumab [ID1652]

### Part 1 – Open session

1. The Chair welcomed the invited clinical and patient experts, Evidence Review Group (ERG)/Assessment Group (AG) representatives and representatives from AstraZeneca
2. The Chair asked all committee members, experts, ERG/AG representatives and NICE staff present to declare any relevant interests

	1. Professor Iain McNeish declared a direct financial interest as he has sat on advisory boards for AstraZeneca, GSK/Tesaro and Clovis Oncology, the companies that manufacture the three PARP inhibitors used in the treatment of ovarian cancer. He also declared an indirect professional financial interest as his institution receives grant income from AstraZeneca.
		1. It was agreed that this declaration would not prevent him from participating in this section of the meeting.
	2. Dr Susana Banerjee declared a direct financial interest as she has received honoraria for speaking engagements and advisory boards from AstraZeneca, GSK/Tesaro, Clovis Oncology and other possible comparator companies. She also declared an indirect professional financial interest as her institution receives funding for research from AstraZeneca and GSK/Tesaro.
		1. It was agreed that this declaration would not prevent her from participating in this section of the meeting.
	3. Ms Rachel Downing declared an indirect professional financial interest as she is employed by Target Ovarian Cancer who receive grants from a number of pharmaceutical companies including AstraZeneca.
		1. It was agreed that this declaration would not prevent her from participating in this section of the meeting.
	4. Dr Alice Turner declared an indirect financial interest as her employer has received grants from AstraZeneca in an unrelated disease area.
		1. It was agreed that this declaration would not prevent her from participating in this section of the meeting.
	5. No further conflicts of interest were declared for this appraisal.
	6. The Chair introduced the lead team who gave presentations on the clinical effectiveness and cost effectiveness of the treatment.
	7. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

### Part 2 – Closed session (company representatives, clinical and patient experts, ERG/AG representatives and members of the public were asked to leave the meeting)

1. The committee discussed confidential information submitted as part of this appraisal.
2. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) was discussed by the committee.
3. The committee decision was based on consensus.

1. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.

## Appraisal of liraglutide for managing overweight and obesity [ID740]

### Part 1 – Open session

1. The Chair welcomed the invited clinical and patient experts, Evidence Review Group (ERG)/Assessment Group (AG) representatives and representatives from NovoNordisk.
2. The Chair asked all committee members, experts, ERG representatives and NICE staff present to declare any relevant interests

	1. Professor Carel le Roux declared a direct financial interest as he has sat on global advisory boards for NovoNordisk and other potential competitor companies. He has also received honorarium for speaking engagements at NovoNordisk and potential competitor companies.
		1. It was agreed that this declaration would not prevent him from participating in this section of the meeting.
	2. Dr Abd Tahrani declared a direct financial interest as he has received financial support for research, speaking engagements and has received honorarium for advisory work from NovoNordisk and potential competitor companies.
		1. It was agreed that this declaration would not prevent him from participating in this section of the meeting.
	3. Ms Sarah Le Brocq declared an indirect professional financial interest as her organisation, HOOP UK has received a grant from NovoNordisk in 2018.
		1. It was agreed that this declaration would not prevent her from participating in this section of the meeting.
	4. No further conflicts of interest were declared for this appraisal.
	5. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.
	6. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

### Part 2 – Closed session (company representatives, clinical and patient experts, ERG/AG representatives and members of the public were asked to leave the meeting)

1. Agreement on the content of the Final Appraisal Determination (FAD) was discussed by the committee.
2. The committee decision was based on consensus.
3. The committee asked the NICE technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.